Prenatal screening for pre-eclampsia: Frequently asked questions

Dagmar Wertaschnigg*, Maya Reddy, Ben W.J. Mol, Daniel L. Rolnik, Fabricio da Silva Costa

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)
7 Downloads (Pure)


The current approach to screening for pre-eclampsia is based on guidelines that rely on medical and obstetric history in early pregnancy to select a high-risk group that might benefit from low-dose aspirin. However, combined screening tests with the addition of biophysical and biochemical measurements have shown significantly better detection rates for preterm pre-eclampsia. Furthermore, the administration of aspirin for the 10% screen-positive group can lead to a significant reduction in severe and preterm forms of pre-eclampsia. This review aims to answer frequently asked questions related to the clinical implementation of screening and the management of screening results.

Original languageEnglish
Pages (from-to)477-483
Number of pages7
JournalAustralian and New Zealand Journal of Obstetrics and Gynaecology
Issue number4
Early online date22 May 2019
Publication statusPublished - Aug 2019


  • aspirin
  • hypertensive disorders in pregnancy
  • pre-eclampsia
  • prevention
  • screening


Dive into the research topics of 'Prenatal screening for pre-eclampsia: Frequently asked questions'. Together they form a unique fingerprint.

Cite this